Dicerna To Present At The Leerink Partners Rare Disease Roundtable

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 4th Annual Rare Disease Roundtable. The presentation will take place on Wednesday, September 30, 2015 at 10:40 a.m. ET at Le Parker Meridien Hotel in New York City.

A live webcast of the presentation can be accessed by visiting “Events & Presentations” in the Investors and Media section on the Company’s website at www.dicerna.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare, inherited diseases involving the liver and for cancers that are genetically defined. The company is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas. In both rare diseases and oncology, Dicerna is pursuing targets that have been difficult to address using conventional approaches, but where connections between targets and diseases are well understood and documented. The company intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.

Help employers find you! Check out all the jobs and post your resume.